arrow
U

Ulrike Schara-Schmidt

University Hospital Essen
H指数:20
被引数:1,570

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Systematic reanalysis of next-generation sequencing data in 101 neuromuscular disorder families enhances diagnostic yield, reveals intronic variants, and identifies a novel disease gene

对101个神经肌肉疾病家系下一代测序数据的系统性再分析提高了诊断率,揭示了内含子变异,并鉴定出一个新的疾病基因

2026-07-200
PRE
Delphi consensus on gene therapy of spinal muscular atrophy with onasemnogene abeparvovec in Germany, Austria and Switzerland—part I—systematic literature review and existing evidence

德国、奥地利和瑞士关于Onasemnogene Abeparvovec治疗脊髓性肌萎缩基因疗法的德尔菲共识——第一部分——系统文献综述与现有证据

2025-11-240
OA
Disease spectrum and long-term prognosis of patients with BAG3-associated neuromuscular diseases in Europe

BAG3相关神经肌肉疾病在欧洲患者中的疾病谱及长期预后。Brain A J. Neurology, awaf223

BRAIN
IF11.7
2025-11-011
PRE
Phenotypic intrafamilial variability of 5q-associated spinal muscular atrophy: A systematic multicentre sibling study

5q相关脊髓性肌萎缩症的表型家族内变异性:一项系统性多中心同胞研究

2025-09-120
PRE
Deciphering DST-associated disorders: biallelic variants affecting DST-b cause a congenital myopathy

解析DST相关疾病:影响DST-b的双等位基因变异导致先天性肌病

Brain
IF11.7
2025-06-110
PRE
Dominant rhabdomyolysis linked to a recurrent ATP2A2 variant reducing SERCA2 function in muscle

显性肌溶解症与复发ATP2A2变异相关,该变异降低了肌肉中SERCA2的功能

BRAIN
IF11.7
2025-05-010
OAAI
Liver function in X-linked myotubular myopathy and autosomal dominant centronuclear myopathy: Data of the unite-CNM study

X-连锁肌管性肌病和常染色体显性中间核肌病中的肝功能:unite-CNM研究的数据

2025-04-240
PRE
Blood biomarker fingerprints in a cohort of patients with CHRNE-related congenital myasthenic syndrome
2025-02-130
OAAI
Safety and efficacy of tamoxifen in non-ambulant patients with Duchenne muscular dystrophy: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial (TAMDMD Group B)

他莫昔芬在杜氏肌营养不良症非行走患者中的安全性与有效性:一项多中心、随机、双盲、安慰剂对照、III期试验(TAMDMD Group B)

2025-02-011
OAAI
Clinical Effectiveness of Newborn Screening for Spinal Muscular Atrophy: A Nonrandomized Controlled Trial
2024-12-010
PRE
Evidentiary basis of the first regulatory qualification of a digital primary efficacy endpoint
2024-11-291
OAAI
AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial

AAV基因治疗杜氏肌营养不良症: EMBARK 3期随机试验

2024-10-093
OAAI
Clinical Effectiveness of Newborn Screening for Spinal Muscular Atrophy
2024-06-0112
PRE